

# CBD Integrated Data Presentation

## Clinical Safety & Efficacy

## Manufacturing & Labeling

Pure Green, LLC

Food and Drug Administration

Silver Spring, Maryland

5.31.2019

Debra Kimless, MD Medical Director

# Clinical Data

6 pilot clinical trials completed

3 multi-center clinical trials underway

Now reporting ...

Single center, mild-to-moderate undifferentiated pain,  
male/female, ages 21-80, N=16

Active ingredients: 5 mg CBD + 0.1 mg terpenes

Wong Baker Faces Pain Rating Scale

Statistically significant  $p < 0.0001$

Clinically significant, mean pain reduction from 5/10 to 1/10  
in <15 minutes

Patients self-reported faster pain reduction than scoring  
system, lasting 4-6 hours, 2 patients more than 24 hours

# Sublingual, Water Soluble CBD tablet

## CMC Data

Finished dosage form – oral, sublingual admin

250 mg, standard pharmaceutical excipients

Unique - CBD/Terpenes rendered water soluble

Unique- leverages entourage effect

Marketed formulation: 20 mg CBD + 0.1 mg terpenes

Validated GMP production conditions

### Clinical Advantages

- Pharmaceutically accurate dosage
- Ease of administration
- No smoking or vaping

# CBD API

## CMC Data

Exceeds USP purity standards

Amber oil, 99.8% CBD

Full quantitative and qualitative data analysis

Extractive process: alcohol, followed by short path fractional distillation

Full IQ/OQ/PQ Validation in process

# Plant Growth Data

Indoor harvest

Selected cultivars

Seed-to-sale tracking on each plant

Finished product is cultivar agnostic

Complete independent QA/QC for over 200 KPI

Safe and efficient production assured\*

\* licensed Michigan Med. Marijuana processor & grower

# Pharmacovigilance

41,000 customers in 10 months

~500,000 dosages

No adverse events

Side effects:

1. Overwhelming sense of well-being

2. Transient drowsiness in ~ 4% patients

following first dosage – we suggest patients take first dose before bedtime to mitigate this issue.

# Product Labeling

